{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T05:27:30Z","timestamp":1791091650158,"version":"4.1.0"},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2013,1]]},"abstract":"<jats:sec>\n                    <jats:title>OBJECTIVE:<\/jats:title>\n                    <jats:p>To estimate the effectiveness of gonadotropin-releasing hormone (GnRH) analogues cotreatment in preventing chemotherapy-induced amenorrhea in young breast cancer patients undergoing cyclophosphamide-based chemotherapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS:<\/jats:title>\n                    <jats:p>One hundred hormone-insensitive breast cancer participants (aged 18-40 years) were recruited from two university-affiliated oncology centers in Egypt. Opting for type of cotreatment was based on available timeframe until start of chemotherapy. Fifty women ready for early chemotherapy were randomized to receive either chemotherapy alone (arm I) or chemotherapy after downregulation (estradiol less than 50 pg\/mL) by GnRH antagonist and agonist (arm II). Then, GnRH antagonist was discontinued and agonist was continued until the end of chemotherapy. When chemotherapy was to start later than 10 days after study inclusion, 50 women were randomized to receive either chemotherapy alone (arm III) or chemotherapy after downregulation with GnRH agonist (arm IV). Resumption of menstruation at 12 months after end of chemotherapy was the primary outcome. Postchemotherapy hormonal and ultrasound changes were secondary outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS:<\/jats:title>\n                    <jats:p>\n                      Twelve months after termination of chemotherapy, there were no differences in menstruation resumption rates between GnRH-treated patients and control group individuals in either early (80% in arms I and II, risk ratio 1, 95% confidence interval 0.7-.32;\n                      <jats:italic toggle=\"yes\">P=<\/jats:italic>\n                      1.00) or delayed chemotherapy groups (80% and 84% in arms III and IV, risk ratio 0.95, 95% confidence interval 0.73-1.235;\n                      <jats:italic toggle=\"yes\">P=<\/jats:italic>\n                      .71). There were no differences in hormonal and ultrasound markers between GnRH analogue users and control group individuals. The use of GnRH analogue cotreatment did not predict independently the odds of menstruating at 12 months.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION:<\/jats:title>\n                    <jats:p>GnRH analogue cotreatment does not offer a significant protective effect on ovarian function in patients treated by cyclophosphamide-based chemotherapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CLINICAL TRIAL REGISTRATION:<\/jats:title>\n                    <jats:p>Australian New Zealand Clinical Trials Registry. www.anzctr.org.au, ACTRN12609001059257.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>LEVEL OF EVIDENCE:<\/jats:title>\n                    <jats:p>I<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/aog.0b013e31827374e2","type":"journal-article","created":{"date-parts":[[2015,10,13]],"date-time":"2015-10-13T14:40:27Z","timestamp":1444747227000},"page":"78-86","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":122,"title":["Gonadatrophin Suppression to Prevent Chemotherapy-Induced Ovarian Damage"],"prefix":"10.1097","volume":"121","author":[{"given":"Eman A.","family":"Elgindy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dahlia O.","family":"El-Haieg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ola M.","family":"Khorshid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eman I.","family":"Ismail","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Abdelgawad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hassan N.","family":"Sallam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed M.","family":"Abou-Setta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-14-20260317","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1053\/j.seminoncol.2009.03.001","article-title":"Breast cancer before age 40 years.","volume":"36","author":"Anders","year":"2009","journal-title":"Semin Oncol"},{"key":"R2-14-20260317","doi-asserted-by":"crossref","first-page":"3324","DOI":"10.1200\/JCO.2007.14.2471","article-title":". Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression.","volume":"26","author":"Anders","year":"2008","journal-title":"J Clin Oncol"},{"key":"R3-14-20260317","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1093\/annonc\/mdi326","article-title":"Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005.","volume":"16","author":"Goldhirsch","year":"2005","journal-title":"Ann Oncol"},{"key":"R4-14-20260317","first-page":"246","article-title":". Invasive breast cancer.","volume":"5","author":"Carlson","year":"2007","journal-title":"J Natl Compr Canc Netw"},{"key":"R5-14-20260317","doi-asserted-by":"crossref","first-page":"10159","DOI":"10.1158\/0008-5472.CAN-07-2042","article-title":"A novel ovarian xenografting model to characterize the impact of chemotherapy agents on human primordial follicle reserve.","volume":"67","author":"Oktem","year":"2007","journal-title":"Cancer Res"},{"key":"R6-14-20260317","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1001\/jama.1979.03300170044028","article-title":"Cytotoxic chemotherapy and gonadal function in patients with Hodgkins disease. Facts and thoughts.","volume":"242","author":"Sutcliffe","year":"1979","journal-title":"JAMA"},{"key":"R7-14-20260317","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1002\/mpo.2950210505","article-title":"Ovarian function following the treatment of childhood acute lymphoblastic leukaemia.","volume":"21","author":"Wallace","year":"1993","journal-title":"Med Pediatr Oncol"},{"key":"R9-14-20260317","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1097\/GRF.0b013e3181f96cb1","article-title":". Use of hormonal protection for chemotherapy-induced gonadotoxicity.","volume":"53","author":"Kim","year":"2010","journal-title":"Clin Obstet Gynecol"},{"key":"R10-14-20260317","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.fertnstert.2010.08.053","article-title":"Combination of gonadotropin-releasing hormone (GnRH) agonists with GnRH antagonists before chemotherapy reduce but does not completely prevent a follicle-stimulating hormone flare-up.","volume":"95","author":"von Wolff","year":"2011","journal-title":"Fertil Steril"},{"key":"R11-14-20260317","first-page":"90","article-title":"Protocol combining GnRH agonists and GnRH antagonists for rapid suppression and prevention of gonadal damage during cytotoxic therapy.","volume":"25","author":"Mardesic","year":"2004","journal-title":"Eur J Gynaecol Oncol"},{"key":"R12-14-20260317","first-page":"257","article-title":"Antagonistic and agonistic GnRH analogue treatment of precocious puberty: tracking gonadotropin concentrations in urine.","volume":"63","author":"Roth","year":"2005","journal-title":"Horm Res"},{"key":"R13-14-20260317","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1080\/09513590701327661","article-title":"Protection of ovarian function and fertility using a combination of gonadotropin-releasing hormone (GnRH) agonist and GnRH antagonist during cancer treatment in young females.","volume":"23","author":"Potolog-Nahari","year":"2007","journal-title":"Gynecol Endocrinol"},{"key":"R14-14-20260317","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1016\/j.fertnstert.2004.12.030","article-title":"Acute depletion of murine primordial follicle reserve by gonadotropin-releasing hormone antagonists.","volume":"83","author":"Danforth","year":"2005","journal-title":"Fertil Steril"},{"key":"R15-14-20260317","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/j.fertnstert.2007.12.044","article-title":"Gonadotropin-releasing hormone agonists for prevention of chemotherapy-induced ovarian damage: prospective randomized study.","volume":"91","author":"Badawy","year":"2009","journal-title":"Fertil Steril"},{"key":"R16-14-20260317","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JCO.2011.36.9850","article-title":"ZORO Study: discrepancy between the conclusion and the results.","volume":"29","author":"Blumenfeld","year":"2011","journal-title":"J Clin Oncol"},{"key":"R17-14-20260317","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1200\/JCO.1996.14.5.1718","article-title":"Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer.","volume":"14","author":"Bines","year":"1996","journal-title":"J Clin Oncol"},{"key":"R19-14-20260317","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1002\/cncr.21385","article-title":"Incidence of chemotherapy-induced, long-term amenorrhea in patients with breast carcinoma age 40 years and younger after adjuvant anthracycline and taxane.","volume":"104","author":"Fornier","year":"2005","journal-title":"Cancer"},{"key":"R20-14-20260317","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1200\/JCO.2010.32.5704","article-title":". Effect of luteinizing hormone-releasing hormone agonist on ovarian function after modern adjuvant breast cancer chemotherapy: the GBG 37 ZORO study.","volume":"29","author":"Gerber","year":"2011","journal-title":"J Clin Oncol"},{"key":"R21-14-20260317","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1200\/JCO.2011.34.6890","article-title":". Randomized trial using gonadotropin-releasing hormone agonist triptorelin for the preservation of ovarian function during (neo)adjuvant chemotherapy for breast cancer.","volume":"30","author":"Munster","year":"2012","journal-title":"J Clin Oncol"},{"key":"R22-14-20260317","first-page":"269","article-title":". Effect of the gonadotropin-releasing hormone analogue triptorelin on the occurrence of chemotherapy-induced early menopause in premenopausal women with breast cancer: a randomized trial.","volume":"306","author":"Del Mastro","year":"2011","journal-title":"JAMA"},{"key":"R24-14-20260317","doi-asserted-by":"crossref","first-page":"e32","DOI":"10.1016\/j.fertnstert.2009.06.004","article-title":"Questioning GnRH analogs for gonadal protection in cancer patients.","volume":"92","author":"Oktay","year":"2009","journal-title":"Fertil Steril"},{"key":"R25-14-20260317","doi-asserted-by":"crossref","first-page":"e155","DOI":"10.1016\/j.fertnstert.2011.07.1112","article-title":"Comment on GnRH analogue cotreatment with chemotherapy for preservation of ovarian function.","volume":"96","author":"Balkenende","year":"2011","journal-title":"Fertil Steril"},{"key":"R26-14-20260317","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.fertnstert.2011.10.040","article-title":". Impact of cancer therapies on ovarian reserve.","volume":"97","author":"Gracia","year":"2012","journal-title":"Fertil Steril"},{"key":"R27-14-20260317","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1634\/theoncologist.12-9-1044","article-title":"How to preserve fertility in young women exposed to chemotherapy The role of GnRH agonist cotreatment in addition to cryopreservation of embrya, oocytes, or ovaries.","volume":"12","author":"Blumenfeld","year":"2007","journal-title":"Oncologist"},{"key":"R28-14-20260317","first-page":"3748","article-title":"Ontogeny of follicle-stimulating hormone receptor gene expression in isolated human ovarian follicles.","volume":"82","author":"Oktay","year":"1997","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Obstetrics &amp; Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00006250-201301000-00014","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T01:00:48Z","timestamp":1773709248000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00006250-201301000-00014"}},"subtitle":["A Randomized Controlled Trial"],"short-title":[],"issued":{"date-parts":[[2013,1]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1097\/aog.0b013e31827374e2","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.717969749.793479105","asserted-by":"object"},{"id-type":"doi","id":"10.3410\/f.717969749.793481259","asserted-by":"object"}]},"ISSN":["0029-7844"],"issn-type":[{"value":"0029-7844","type":"print"}],"subject":[],"published":{"date-parts":[[2013,1]]}}}